The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Rational designs of in vivo CRISPR-Cas delivery systems
Abstract
The CRISPR-Cas system initiated a revolution in genome editing when it was, for the first time, demonstrated success in the mammalian cells. Today, scientists are able to readily edit the genome, regulate gene transcription, engineer posttranscriptional events, and image nucleic acids using CRISPR-Cas-based tools. However, to efficiently transport CRISPR-Cas into target tissues/cells remains challenging due to many extra- and intra-cellular barriers, therefore largely limiting the applications of CRISPR-based therapeutics in vivo. In this review, we summarize the features of plasmid-, RNA- and ribonucleoprotein (RNP)-based CRISPR-Cas therapeutics. Then, we survey the current in vivo delivery systems. Finally, we specify the requirements for efficient in vivo delivery in clinical settings, and highlight both efficiency and safety for different CRISPR-Cas tools.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
A Toll-like receptor recognizes bacterial DNA
Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. (2000) · Nature · doi:10.1038/35047123 · Cited by 6,491
Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage
Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A., & Liu, D. R. (2016) · Nature · doi:10.1038/nature17946 · Cited by 5,437
Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression
Qi, L. S., Larson, M. H., Gilbert, L. A., Doudna, J. A., Weissman, J. S., Arkin, A. P., & Lim, W. A. (2013) · Cell · doi:10.1016/j.cell.2013.02.022 · Cited by 5,016
Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage
Gaudelli, N. M., Komor, A. C., Rees, H. A., Packer, M. S., Badran, A. H., Bryson, D. I., & Liu, D. R. (2017) · Nature · doi:10.1038/nature24644 · Cited by 4,184
CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes
Gilbert, L. A., Larson, M. H., Morsut, L., Liu, Z., Brar, G. A., Torres, S. E., Stern-Ginossar, N., Brandman, O., Whitehead, E. H., Doudna, J. A., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.044 · Cited by 3,696
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
Konermann, S., Brigham, M. D., Trevino, A. E., Joung, J., Abudayyeh, O. O., Barcena, C., Hsu, P. D., Habib, N., Gootenberg, J. S., Nishimasu, H., et al. (2015) · Nature · doi:10.1038/nature14136 · Cited by 2,825
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
Crystal structure of Cas9 in complex with guide RNA and target DNA
Nishimasu, H., Ran, F. A., Hsu, P. D., Konermann, S., Shehata, S. I., Dohmae, N., Ishitani, R., Zhang, F., & Nureki, O. (2014) · Cell · doi:10.1016/j.cell.2014.02.001 · Cited by 2,306
RNA targeting with CRISPR–Cas13
Abudayyeh, O. O., Gootenberg, J. S., Essletzbichler, P., Han, S., Joung, J., Belanto, J. J., Verdine, V., Cox, D. B. T., Kellner, M. J., Regev, A., et al. (2017) · Nature · doi:10.1038/nature24049 · Cited by 2,093
CRISPR–Cas9 Structures and Mechanisms
Jiang, F., & Doudna, J. A. (2017) · Annual Review of Biophysics · doi:10.1146/annurev-biophys-062215-010822 · Cited by 2,029
Kim, S., Kim, D., Cho, S. W., Kim, J., & Kim, J.-S. (2014) · Genome Research · doi:10.1101/gr.171322.113 · Cited by 1,856
A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738
Evolved Cas9 variants with broad PAM compatibility and high DNA specificity
Hu, J. H., Miller, S. M., Geurts, M. H., Tang, W., Chen, L., Sun, N., Zeina, C. M., Gao, X., Rees, H. A., Lin, Z., et al. (2018) · Nature · doi:10.1038/nature26155 · Cited by 1,552
Zuris, J. A., Thompson, D. B., Shu, Y., Guilinger, J. P., Bessen, J. L., Hu, J. H., Maeder, M. L., Joung, J. K., Chen, Z.-Y., & Liu, D. R. (2015) · Nature Biotechnology · doi:10.1038/nbt.3081 · Cited by 1,460
CRISPR-Cas guides the future of genetic engineering
Knott, G. J., & Doudna, J. A. (2018) · Science · doi:10.1126/science.aat5011 · Cited by 1,410
High-throughput functional genomics using CRISPR-Cas9
Shalem, O., Sanjana, N. E., & Zhang, F. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3899 · Cited by 1,233
Delivering CRISPR: a review of the challenges and approaches
Lino, C. A., Harper, J. C., Carney, J. P., & Timlin, J. A. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1474964 · Cited by 1,185
Maruyama, T., Dougan, S. K., Truttmann, M. C., Bilate, A. M., Ingram, J. R., & Ploegh, H. L. (2015) · Nature Biotechnology · doi:10.1038/nbt.3190 · Cited by 1,137
Identification of preexisting adaptive immunity to Cas9 proteins in humans
Charlesworth, C. T., Deshpande, P. S., Dever, D. P., Camarena, J., Lemgart, V. T., Cromer, M. K., Vakulskas, C. A., Collingwood, M. A., Zhang, L., Bode, N. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0326-x · Cited by 1,093
Effect of genome size on AAV vector packaging
Wu, Z., Yang, H., & Colosi, P. (2010) · Molecular Therapy · doi:10.1038/mt.2009.255 · Cited by 1,029
Engineering complex synthetic transcriptional programs with CRISPR RNA scaffolds
Zalatan, J. G., Lee, M. E., Almeida, R., Gilbert, L. A., Whitehead, E. H., La Russa, M., Tsai, J. C., Weissman, J. S., Dueber, J. E., Qi, L. S., et al. (2015) · Cell · doi:10.1016/j.cell.2014.11.052 · Cited by 938
Finn, J. D., Smith, A. R., Patel, M. C., Shaw, L., Youniss, M. R., van Heteren, J., Dirstine, T., Ciullo, C., Lescarbeau, R., Seitzer, J., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.02.014 · Cited by 878
Yin, H., Song, C.-Q., Dorkin, J. R., Zhu, L. J., Li, Y., Wu, Q., Park, A., Yang, J., Suresh, S., Bizhanova, A., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3471 · Cited by 876
CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells
Dever, D. P., Bak, R. O., Reinisch, A., Camarena, J., Washington, G., Nicolas, C. E., Pavel-Dinu, M., Saxena, N., Wilkens, A. B., Mantri, S., et al. (2016) · Nature · doi:10.1038/nature20134 · Cited by 864
Engineering adeno-associated viruses for clinical gene therapy
Kotterman, M. A., & Schaffer, D. V. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3742 · Cited by 761
Lee, K., Conboy, M., Park, H. M., Jiang, F., Kim, H. J., Dewitt, M. A., Mackley, V. A., Chang, K., Rao, A., Skinner, C., et al. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0137-2 · Cited by 755
In vivo genome editing with a small Cas9 orthologue derived from Campylobacter jejuni
Kim, E., Koo, T., Park, S. W., Kim, D., Kim, K., Cho, H.-Y., Song, D. W., Lee, K. J., Jung, M. H., Kim, S., et al. (2017) · Nature Communications · doi:10.1038/ncomms14500 · Cited by 715
Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA
Ramakrishna, S., Kwaku Dad, A.-B., Beloor, J., Gopalappa, R., Lee, S.-K., & Kim, H. (2014) · Genome Research · doi:10.1101/gr.171264.113 · Cited by 655
Self‐assembled DNA nanoclews for the efficient delivery of CRISPR–Cas9 for genome editing
Sun, W., Ji, W., Hall, J. M., Hu, Q., Wang, C., Beisel, C. L., & Gu, Z. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201506030 · Cited by 629
Self-citationDelivery technologies for genome editing
Yin, H., Kauffman, K. J., & Anderson, D. G. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.280 · Cited by 597
Direct cytosolic delivery of CRISPR/Cas9-ribonucleoprotein for efficient gene editing
Mout, R., Ray, M., Yesilbag Tonga, G., Lee, Y.-W., Tay, T., Sasaki, K., & Rotello, V. M. (2017) · ACS Nano · doi:10.1021/acsnano.6b07600 · Cited by 579
Wang, H.-X., Li, M., Lee, C. M., Chakraborty, S., Kim, H.-W., Bao, G., & Leong, K. W. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00799 · Cited by 560
Ishino, Y., Krupovic, M., & Forterre, P. (2018) · Journal of Bacteriology · doi:10.1128/jb.00580-17 · Cited by 558
Miller, J. B., Zhang, S., Kos, P., Xiong, H., Zhou, K., Perelman, S. S., Zhu, H., & Siegwart, D. J. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201610209 · Cited by 540
Alsaiari, S. K., Patil, S., Alyami, M., Alamoudi, K. O., Aleisa, F. A., Merzaban, J. S., Li, M., & Khashab, N. M. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.7b11754 · Cited by 517
Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing
Yin, H., Song, C.-Q., Suresh, S., Wu, Q., Walsh, S., Rhym, L. H., Mintzer, E., Bolukbasi, M. F., Zhu, L. J., Kauffman, K., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.4005 · Cited by 499
Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates
Dong, Y., Love, K. T., Dorkin, J. R., Sirirungruang, S., Zhang, Y., Chen, D., Bogorad, R. L., Yin, H., Chen, Y., Vegas, A. J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1322937111 · Cited by 488
Self-citationKim, S. M., Yang, Y., Oh, S. J., Hong, Y., Seo, M., & Jang, M. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.013 · Cited by 481
Small molecules enhance CRISPR genome editing in pluripotent stem cells
Yu, C., Liu, Y., Ma, T., Liu, K., Xu, S., Zhang, Y., Liu, H., La Russa, M., Xie, M., Ding, S., et al. (2015) · Cell stem cell · doi:10.1016/j.stem.2015.01.003 · Cited by 455
Self-citationGrieger, J. C., & Samulski, R. J. (2005) · Journal of Virology · doi:10.1128/jvi.79.15.9933-9944.2005 · Cited by 419
Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities
Li, L., Hu, S., & Chen, X. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.04.031 · Cited by 415
Liu, J., Chang, J., Jiang, Y., Meng, X., Sun, T., Mao, L., Xu, Q., & Wang, M. (2019) · Advanced Materials · doi:10.1002/adma.201902575 · Cited by 373
Billon, P., Bryant, E. E., Joseph, S. A., Nambiar, T. S., Hayward, S. B., Rothstein, R., & Ciccia, A. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.08.008 · Cited by 363
Lee, B., Lee, K., Panda, S., Gonzales-Rojas, R., Chong, A., Bugay, V., Park, H. M., Brenner, R., Murthy, N., & Lee, H. Y. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0252-8 · Cited by 361
Anderson, B. R., Muramatsu, H., Jha, B. K., Silverman, R. H., Weissman, D., & Kariko, K. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr586 · Cited by 356
CRISPR-STOP: gene silencing through base-editing-induced nonsense mutations
Kuscu, C., Parlak, M., Tufan, T., Yang, J., Szlachta, K., Wei, X., Mammadov, R., & Adli, M. (2017) · Nature Methods · doi:10.1038/nmeth.4327 · Cited by 344
Li, Z., Zhou, X., Wei, M., Gao, X., Zhao, L., Shi, R., Sun, W., Duan, Y., Yang, G., & Yuan, L. (2019) · Nano Letters · doi:10.1021/acs.nanolett.8b02689 · Cited by 318
Chen, Z., Liu, F., Chen, Y., Liu, J., Wang, X., Chen, A. T., Deng, G., Zhang, H., Liu, J., Hong, Z., et al. (2017) · Advanced Functional Materials · doi:10.1002/adfm.201703036 · Cited by 297
A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo
Jiang, C., Mei, M., Li, B., Zhu, X., Zu, W., Tian, Y., Wang, Q., Guo, Y., Dong, Y., & Tan, X. (2017) · Cell Research · doi:10.1038/cr.2017.16 · Cited by 295
Wang, H.-X., Song, Z., Lao, Y.-H., Xu, X., Gong, J., Cheng, D., Chakraborty, S., Park, J. S., Li, M., Huang, D., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712963115 · Cited by 277
Vaidyanathan, S., Azizian, K. T., Haque, A. K. M. A., Henderson, J. M., Hendel, A., Shore, S., Antony, J. S., Hogrefe, R. I., Kormann, M. S. D., Porteus, M. H., et al. (2018) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2018.06.010 · Cited by 262
Advances in therapeutic CRISPR/Cas9 genome editing
Savić, N., & Schwank, G. (2016) · Translational Research · doi:10.1016/j.trsl.2015.09.008 · Cited by 257
Locus-specific histone deacetylation using a synthetic CRISPR-Cas9-based HDAC
Kwon, D. Y., Zhao, Y.-T., Lamonica, J. M., & Zhou, Z. (2017) · Nature Communications · doi:10.1038/ncomms15315 · Cited by 246
Artificial Virus Delivers CRISPR-Cas9 System for Genome Editing of Cells in Mice
Li, L., Song, L., Liu, X., Yang, X., Li, X., He, T., Wang, N., Yang, S., Yu, C., Yin, T., et al. (2017) · ACS Nano · doi:10.1021/acsnano.6b04261 · Cited by 244
Targeted DNA methylation in vivo using an engineered dCas9-MQ1 fusion protein
Lei, Y., Zhang, X., Su, J., Jeong, M., Gundry, M. C., Huang, Y.-H., Zhou, Y., Li, W., & Goodell, M. A. (2017) · Nature Communications · doi:10.1038/ncomms16026 · Cited by 218
Lipid nanoparticle-mediated efficient delivery of CRISPR/Cas9 for tumor therapy
Zhang, L., Wang, P., Feng, Q., Wang, N., Chen, Z., Huang, Y., Zheng, W., & Jiang, X. (2017) · NPG Asia Materials · doi:10.1038/am.2017.185 · Cited by 218
Receptor-Mediated Delivery of CRISPR-Cas9 Endonuclease for Cell-Type-Specific Gene Editing
Rouet, R., Thuma, B. A., Roy, M. D., Lintner, N. G., Rubitski, D. M., Finley, J. E., Wisniewska, H. M., Mendonsa, R., Hirsh, A., de Oñate, L., et al. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b01551 · Cited by 163
Graphene oxide-mediated Cas9/sgRNA delivery for efficient genome editing
Yue, H., Zhou, X., Cheng, M., & Xing, D. (2018) · Nanoscale · doi:10.1039/c7nr07999k · Cited by 150
Current and future delivery systems for engineered nucleases: ZFN, TALEN and RGEN
Ain, Q. U., Chung, J. Y., & Kim, Y.-H. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.036 · Cited by 130
Palermo, G., Chen, J. S., Ricci, C. G., Rivalta, I., Jinek, M., Batista, V. S., Doudna, J. A., & McCammon, J. A. (2018) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583518000070 · Cited by 123
Biodegradable Amino-Ester Nanomaterials for Cas9 mRNA Delivery in Vitro and in Vivo
Zhang, X., Li, B., Luo, X., Zhao, W., Jiang, J., Zhang, C., Gao, M., Chen, X., & Dong, Y. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b08163 · Cited by 107
Research works printed but not linked: 140
- Cong, 2013, Multiplex genome engineering using CRISPR/Cas systems, Science, 339, 819, 10.1126/science.1231143 · DOI · Paper page
- Adli, 2018, The CRISPR tool kit for genome editing and beyond, Nat. Commun., 9, 1911, 10.1038/s41467-018-04252-2 · DOI · Paper page
- Hsu, 2014, Development and applications of CRISPR-Cas9 for genome engineering, Cell, 157, 1262, 10.1016/j.cell.2014.05.010 · DOI · Paper page
- Nelson, 2019, Long-term evaluation of AAV-CRISPR genome editing for duchenne muscular dystrophy, Nat. Med., 25, 427, 10.1038/s41591-019-0344-3 · DOI · Paper page
- Wu, 2019, Highly efficient therapeutic gene editing of human hematopoietic stem cells, Nat. Med., 25, 776, 10.1038/s41591-019-0401-y · DOI · Paper page
- Pavel-Dinu, 2019, Gene correction for SCID-X1 in long-term hematopoietic stem cells, Nat. Commun., 10, 2021, 10.1038/s41467-019-10080-9 · DOI
- de Buhr, 2018, Harnessing CRISPR to combat human viral infections, Curr. Opin. Immunol., 54, 123, 10.1016/j.coi.2018.06.002 · DOI
- Ewart, 2019, Gene editing for inflammatory disorders, Ann. Rheum. Dis., 78, 6, 10.1136/annrheumdis-2018-213454 · DOI
- Yin, 2019, CRISPR-Cas: a tool for cancer research and therapeutics, Nat. Rev. Clin. Oncol., 16, 281, 10.1038/s41571-019-0166-8 · DOI · Paper page
- Gao, 2019, Therapeutic potential of CRISPR/Cas9 gene editing in engineered T-cell therapy, Cancer Med., 8, 4254, 10.1002/cam4.2257 · DOI
- Tan, 2019, Engineering of high-precision base editors for site-specific single nucleotide replacement, Nat. Commun., 10, 439, 10.1038/s41467-018-08034-8 · DOI · Paper page
- Wu, 2019, Progress and challenges for live-cell imaging of genomic loci using CRISPR-based platforms, Genomics, Proteomics Bioinf., 17, 119
- Wilbie, 2019, Delivery aspects of CRISPR/Cas for in vivo genome editing, Acc. Chem. Res., 52, 1555, 10.1021/acs.accounts.9b00106 · DOI · Paper page
- Wan, 2019, Material solutions for delivery of CRISPR/Cas-based genome editing tools: current status and future outlook, Mater. Today, 26, 40, 10.1016/j.mattod.2018.12.003 · DOI
- Eoh, 2019, Biomaterials as vectors for the delivery of CRISPR-Cas9, Biomater. Sci., 7, 1240, 10.1039/C8BM01310A · DOI
- Givens, 2018, Nanoparticle-based delivery of CRISPR/Cas9 genome-editing therapeutics, AAPS J., 20, 108, 10.1208/s12248-018-0267-9 · DOI
- Piotrowski-Daspit, 2018, Debugging the genetic code: non-viral in vivo delivery of therapeutic genome editing technologies, Curr. Opin. Biomed. Eng., 7, 24, 10.1016/j.cobme.2018.08.002 · DOI
- Mout, 2017, In vivo delivery of CRISPR/Cas9 for therapeutic gene editing: progress and challenges, Bioconjug. Chem., 28, 880, 10.1021/acs.bioconjchem.7b00057 · DOI · Paper page
- Wang, 2019, Delivery of CRISPR/Cas9 by novel strategies for gene therapy, Chembiochem, 20, 634, 10.1002/cbic.201800629 · DOI
- LaFountaine, 2015, Delivery and therapeutic applications of gene editing technologies ZFNs, TALENs, and CRISPR/Cas9, Int. J. Pharm., 494, 180, 10.1016/j.ijpharm.2015.08.029 · DOI · Paper page
- Ishino, 1987, Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product, J. Bacteriol., 169, 5429, 10.1128/jb.169.12.5429-5433.1987 · DOI · Paper page
- Mojica, 2000, Biological significance of a family of regularly spaced repeats in the genomes of archaea, bacteria and mitochondria, Mol. Microbiol., 36, 244, 10.1046/j.1365-2958.2000.01838.x · DOI · Paper page
- Mojica, 2005, Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements, J. Mol. Evol., 60, 174, 10.1007/s00239-004-0046-3 · DOI · Paper page
- Pourcel, 2005, CRISPR elements in Yersinia pestis acquire new repeats by preferential uptake of bacteriophage DNA, and provide additional tools for evolutionary studies, Microbiology, 151, 653, 10.1099/mic.0.27437-0 · DOI · Paper page
- Bolotin, 2005, Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin, Microbiology, 151, 2551, 10.1099/mic.0.28048-0 · DOI · Paper page
- Makarova, 2002, A DNA repair system specific for thermophilic archaea and bacteria predicted by genomic context analysis, Nucleic Acids Res., 30, 482, 10.1093/nar/30.2.482 · DOI · Paper page
- Jansen, 2002, Identification of genes that are associated with DNA repeats in prokaryotes, Mol. Microbiol., 43, 1565, 10.1046/j.1365-2958.2002.02839.x · DOI · Paper page
- Barrangou, 2007, CRISPR provides acquired resistance against viruses in prokaryotes, Science, 315, 1709, 10.1126/science.1138140 · DOI · Paper page
- Brouns, 2008, Small CRISPR RNAs guide antiviral defense in prokaryotes, Science, 321, 960, 10.1126/science.1159689 · DOI · Paper page
- Marraffini, 2008, CRISPR interference limits horizontal gene transfer in staphylococci by targeting DNA, Science, 322, 1843, 10.1126/science.1165771 · DOI · Paper page
- Garneau, 2010, The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA, Nature, 468, 67, 10.1038/nature09523 · DOI · Paper page
- Jinek, 2012, A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity, Science, 337, 816, 10.1126/science.1225829 · DOI · Paper page
- Qi, 2013, Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression, Cell, 152, 1173, 10.1016/j.cell.2013.02.022 · DOI · Paper page
- Maeder, 2013, CRISPR RNA-guided activation of endogenous human genes, Nat. Methods, 10, 977, 10.1038/nmeth.2598 · DOI · Paper page
- Perez-Pinera, 2013, RNA-guided gene activation by CRISPR-Cas9-based transcription factors, Nat. Methods, 10, 973, 10.1038/nmeth.2600 · DOI · Paper page
- Chavez, 2015, Highly efficient Cas9-mediated transcriptional programming, Nat. Methods, 12, 326, 10.1038/nmeth.3312 · DOI · Paper page
- Tanenbaum, 2014, A protein-tagging system for signal amplification in gene expression and fluorescence imaging, Cell, 159, 635, 10.1016/j.cell.2014.09.039 · DOI · Paper page
- Kuscu, 2016, CRISPR-Cas9-AID base editor is a powerful gain-of-function screening tool, Nat. Methods, 13, 983, 10.1038/nmeth.4076 · DOI
- Morita, 2016, Targeted DNA demethylation in vivo using dCas9-peptide repeat and scFv-TET1 catalytic domain fusions, Nat. Biotechnol., 34, 1060, 10.1038/nbt.3658 · DOI · Paper page
- Kearns, 2015, Functional annotation of native enhancers with a Cas9-histone demethylase fusion, Nat. Methods, 12, 401, 10.1038/nmeth.3325 · DOI · Paper page
- Liang, 2011, Engineering the ABA plant stress pathway for regulation of induced proximity, Sci. Signal., 4, 10.1126/scisignal.2001449 · DOI · Paper page
- Qin, 2017, Live cell imaging of low- and non-repetitive chromosome loci using CRISPR-Cas9, Nat. Commun., 8, 14725, 10.1038/ncomms14725 · DOI · Paper page
- Tsoi, 2010, Characterization of condensed plasmid DNA models for studying the direct effect of ionizing radiation, Biophys. Chem., 147, 104, 10.1016/j.bpc.2009.12.006 · DOI
- Fritz, 2002, Electronic detection of DNA by its intrinsic molecular charge, Proc. Natl. Acad. Sci. U. S. A., 99, 14142, 10.1073/pnas.232276699 · DOI · Paper page
- Luo, 2018, Macrophage-specific in vivo gene editing using cationic lipid-assisted polymeric nanoparticles, ACS Nano, 12, 994, 10.1021/acsnano.7b07874 · DOI · Paper page
- Smoyer, 2014, Breaking down the wall: the nuclear envelope during mitosis, Curr. Opin. Cell Biol., 26, 1, 10.1016/j.ceb.2013.08.002 · DOI
- Branden, 1999, A peptide nucleic acid-nuclear localization signal fusion that mediates nuclear transport of DNA, Nat. Biotechnol., 17, 784, 10.1038/11726 · DOI · Paper page
- Copolovici, 2014, Cell-penetrating peptides: design, synthesis, and applications, ACS Nano, 8, 1972, 10.1021/nn4057269 · DOI · Paper page
- Wu, 2016, Translation dynamics of single mRNAs in live cells and neurons, Science, 352, 1430, 10.1126/science.aaf1084 · DOI · Paper page
- Bak, 2015, Chemically modified guide RNAs enhance CRISPR/Cas genome editing in human primary cells, Hum. Gene Ther., 26, A11
- DeWitt, 2017, Genome editing via delivery of Cas9 ribonucleoprotein, Methods, 121-122, 9, 10.1016/j.ymeth.2017.04.003 · DOI · Paper page
- Gagnon, 2014, Efficient mutagenesis by Cas9 protein-mediated oligonucleotide insertion and large-scale assessment of single-guide RNAs, PLoS One, 9, 10.1371/journal.pone.0098186 · DOI · Paper page
- Wright, 2015, Rational design of a split-Cas9 enzyme complex, Proc. Natl. Acad. Sci. U. S. A., 112, 2984, 10.1073/pnas.1501698112 · DOI · Paper page
- Hansen-Bruhn, 2018, Active intracellular delivery of a Cas9/sgRNA complex using ultrasound-propelled nanomotors, Angew. Chem. Int. Ed., 57, 2657, 10.1002/anie.201713082 · DOI · Paper page
- Crudele, 2018, Cas9 immunity creates challenges for CRISPR gene editing therapies, Nat. Commun., 9, 3497, 10.1038/s41467-018-05843-9 · DOI · Paper page
- Song, 2016, RS-1 enhances CRISPR/Cas9- and TALEN-mediated knock-in efficiency, Nat. Commun., 7, 10548, 10.1038/ncomms10548 · DOI · Paper page
- Cao, 2019, Nontoxic nanopore electroporation for effective intracellular delivery of biological macromolecules, Proc. Natl. Acad. Sci. U. S. A., 116, 7899, 10.1073/pnas.1818553116 · DOI
- Wu, 2017, Efficient in vivo gene editing using ribonucleoproteins in skin stem cells of recessive dystrophic epidermolysis bullosa mouse model, Proc. Natl. Acad. Sci. U. S. A., 114, 1660, 10.1073/pnas.1614775114 · DOI
- Maresch, 2016, Multiplexed pancreatic genome engineering and cancer induction by transfection-based CRISPR/Cas9 delivery in mice, Nat. Commun., 7, 10770, 10.1038/ncomms10770 · DOI · Paper page
- Han, 2015, CRISPR-Cas9 delivery to hard-to-transfect cells via membrane deformation, Sci. Adv., 1, 10.1126/sciadv.1500454 · DOI · Paper page
- Wirth, 2013, History of gene therapy, Gene, 525, 162, 10.1016/j.gene.2013.03.137 · DOI · Paper page
- Samulski, 2014, AAV-mediated gene therapy for research and therapeutic purposes, Annu. Rev. Virol., 1, 427, 10.1146/annurev-virology-031413-085355 · DOI · Paper page
- Xu, 2019, Development of "CLAN" nanomedicine for nucleic acid therapeutics, Small, 15, 10.1002/smll.201900055 · DOI
- Yang, 2011, Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy, J. Control. Release, 156, 203, 10.1016/j.jconrel.2011.07.035 · DOI · Paper page
- Xu, 2016, Tumor acidity-sensitive linkage-bridged block copolymer for therapeutic siRNA delivery, Biomaterials, 88, 48, 10.1016/j.biomaterials.2016.02.031 · DOI
- Liu, 2018, Systemic delivery of CRISPR/Cas9 with PEG-PLGA nanoparticles for chronic myeloid leukemia targeted therapy, Biomater. Sci., 6, 1592, 10.1039/C8BM00263K · DOI
- Burke, 2010, BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia, Leukemia, 24, 1105, 10.1038/leu.2010.67 · DOI
- Liu, 2018, Optimization of lipid-assisted nanoparticle for disturbing neutrophils-related inflammation, Biomaterials, 172, 92, 10.1016/j.biomaterials.2018.04.052 · DOI
- Li, 2018, Optimized nanoparticle-mediated delivery of CRISPR-Cas9 system for B cell intervention, Nano Res., 11, 6270, 10.1007/s12274-018-2150-5 · DOI
- Holness, 1993, Molecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins, Blood, 81, 1607, 10.1182/blood.V81.6.1607.1607 · DOI · Paper page
- Schuh, 2018, Gene editing of MPS I human fibroblasts by co-delivery of a CRISPR/Cas9 plasmid and a donor oligonucleotide using nanoemulsions as nonviral carriers, Eur. J. Pharm. Biopharm., 122, 158, 10.1016/j.ejpb.2017.10.017 · doi:10.1016/j.ejpb.2017.10.017
- He, 2018, In vivo ovarian cancer gene therapy using CRISPR-Cas9, Hum. Gene Ther., 29, 223, 10.1089/hum.2017.209 · DOI
- Li, 2019, Knockdown of hypoxia-inducible factor-1 alpha by tumor targeted delivery of CRISPR/Cas9 system suppressed the metastasis of pancreatic cancer, J. Control. Release, 304, 204, 10.1016/j.jconrel.2019.05.019 · DOI
- Dharmalingam, 2017, Green transfection: cationic lipid nanocarrier system derivatized from vegetable fat, palmstearin enhances nucleic acid transfections, ACS Omega, 2, 7892, 10.1021/acsomega.7b00935 · DOI
- Zhang, 2019, Cationic polymer-mediated CRISPR/Cas9 plasmid delivery for genome editing, Macromol. Rapid Commun., 40, 10.1002/marc.201800068 · DOI
- Ryu, 2018, Effective PEI-mediated delivery of CRISPR-Cas9 complex for targeted gene therapy, Nanomedicine, 14, 2095, 10.1016/j.nano.2018.06.009 · DOI
- Yan, 2015, Modulation of gene expression by polymer nanocapsule delivery of DNA cassettes encoding small RNAs, PLoS One, 10
- Liang, 2017, Tumor cell-targeted delivery of CRISPR/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGFA in osteosarcoma, Biomaterials, 147, 68, 10.1016/j.biomaterials.2017.09.015 · DOI · Paper page
- Liu, 2019, Multistage delivery nanoparticle facilitates efficient CRISPR/dCas9 activation and tumor growth suppression in vivo, Adv. Sci., 6, 1801423, 10.1002/advs.201801423 · DOI · Paper page
- Wang, 2014, A fluorinated dendrimer achieves excellent gene transfection efficacy at extremely low nitrogen to phosphorus ratios, Nat. Commun., 5, 3053, 10.1038/ncomms4053 · DOI · Paper page
- Qi, 2018, Fluorinated acid-labile branched hydroxyl-rich nanosystems for flexible and robust delivery of plasmids, Small, 14, 10.1002/smll.201803061 · DOI
- Lehto, 2016, Peptides for nucleic acid delivery, Adv. Drug Deliv. Rev., 106, 172, 10.1016/j.addr.2016.06.008 · DOI · Paper page
- Wang, 2018, Thermo-triggered release of CRISPR-Cas9 system by lipid-encapsulated gold nanoparticles for tumor therapy, Angew. Chem. Int. Ed., 57, 1491, 10.1002/anie.201708689 · DOI · Paper page
- Timin, 2018, Efficient gene editing via non-viral delivery of CRISPR-Cas9 system using polymeric and hybrid microcarriers, Nanomedicine, 14, 97, 10.1016/j.nano.2017.09.001 · DOI
- Lu, 2011, Ionic polypeptides with unusual helical stability, Nat. Commun., 2, 206, 10.1038/ncomms1209 · DOI · Paper page
- Lao, 2018, HPV oncogene manipulation using nonvirally delivered CRISPR/Cas9 or natronobacterium gregoryi argonaute, Adv. Sci., 5, 1700540, 10.1002/advs.201700540 · DOI
- Zhang, 2019, CRISPR/Cas9 delivery mediated with hydroxyl-rich nanosystems for gene editing in aorta, Adv. Sci., 6, 1900386, 10.1002/advs.201900386 · DOI
- Liu, 2018, Tumor targeted genome editing mediated by a multi-functional gene vector for regulating cell behaviors, J. Control. Release, 291, 90, 10.1016/j.jconrel.2018.10.018 · DOI
- Zhu, 2018, Nanoparticles based on poly (beta-amino ester) and HPV16-targeting CRISPR/shRNA as potential drugs for HPV16-related cervical malignancy, Mol. Ther., 26, 2443, 10.1016/j.ymthe.2018.07.019 · DOI
- Lin, 2018, Exosome-liposome hybrid nanoparticles deliver CRISPR/Cas9 system in MSCs, Adv. Sci., 5, 1700611, 10.1002/advs.201700611 · DOI · Paper page
- Killian, 2019, Antibody-targeted chromatin enables effective intracellular delivery and functionality of CRISPR/Cas9 expression plasmids, Nucleic Acids Res., 47, 10.1093/nar/gkz137 · DOI
- Guo, 2019, Therapeutic genome editing of triple-negative breast tumors using a noncationic and deformable nanolipogel, Proc. Natl. Acad. Sci. U. S. A., 116, 18295, 10.1073/pnas.1904697116 · DOI
- Li, 2019, A rationally designed semiconducting polymer brush for NIR-II imaging-guided light-triggered remote control of CRISPR/Cas9 genome editing, Adv. Mater., 31
- Zhang, 2019, Genome editing with mRNA encoding ZFN, TALEN, and Cas9, Mol. Ther., 27, 735, 10.1016/j.ymthe.2019.01.014 · DOI · Paper page
- Xu, 2018, Targeting of NLRP3 inflammasome with gene editing for the amelioration of inflammatory diseases, Nat. Commun., 9, 4092, 10.1038/s41467-018-06522-5 · DOI · Paper page
- Zhang, 2019, In situ repurposing of dendritic cells with CRISPR/Cas9-based nanomedicine to induce transplant tolerance, Biomaterials, 217, 119302, 10.1016/j.biomaterials.2019.119302 · DOI
- Liu, 2016, Recent progress of microfluidics in translational applications, Adv. Healthcare Mater., 5, 871, 10.1002/adhm.201600009 · DOI
- Maeki, 2018, Advances in microfluidics for lipid nanoparticles and extracellular vesicles and applications in drug delivery systems, Adv. Drug Deliv. Rev., 128, 84, 10.1016/j.addr.2018.03.008 · DOI · Paper page
- Li, 2015, An orthogonal array optimization of lipid-like nanoparticles for mRNA delivery in vivo, Nano Lett., 15, 8099, 10.1021/acs.nanolett.5b03528 · DOI · Paper page
- Usman, 2018, Efficient RNA drug delivery using red blood cell extracellular vesicles, Nat. Commun., 9, 2359, 10.1038/s41467-018-04791-8 · DOI · Paper page
- Sun, 2014, Cocoon-like self-degradable DNA nanoclew for anticancer drug delivery, J. Am. Chem. Soc., 136, 14722, 10.1021/ja5088024 · DOI · Paper page
- Gasiunas, 2012, Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria, Proc. Natl. Acad. Sci. U. S. A., 109, E2579, 10.1073/pnas.1208507109 · DOI · Paper page
- Chen, 2019, A biodegradable nanocapsule delivers a Cas9 ribonucleoprotein complex for in vivo genome editing, Nat. Nanotechnol., 14, 974, 10.1038/s41565-019-0539-2 · DOI · Paper page
- Shahbazi, 2019, Targeted homology-directed repair in blood stem and progenitor cells with CRISPR nanoformulations, Nat. Mater., 18, 1124, 10.1038/s41563-019-0385-5 · DOI · Paper page
- Ray, 2018, CRISPRed macrophages for cell-based cancer immunotherapy, Bioconjug. Chem., 29, 445, 10.1021/acs.bioconjchem.7b00768 · DOI
- Wang, 2016, Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles, Proc. Natl. Acad. Sci. U. S. A., 113, 2868, 10.1073/pnas.1520244113 · DOI · Paper page
- Li, 2019, Intracellular delivery and biodistribution study of CRISPR/Cas9 ribonucleoprotein loaded bioreducible lipidoid nanoparticles, Biomater. Sci., 7, 596, 10.1039/C8BM00637G · DOI
- Kang, 2018, Nonviral genome editing based on a polymer-derivatized CRISPR nanocomplex for targeting bacterial pathogens and antibiotic resistance, Bioconjug. Chem., 29, 3936, 10.1021/acs.bioconjchem.8b00771 · DOI
- Cho, 2019, Lecithin nano-liposomal particle as a CRISPR/Cas9 complex delivery system for treating type 2 diabetes, J. Nanobiotechnol., 17, 19, 10.1186/s12951-019-0452-8 · DOI
- Kim, 2018, Simple in vivo gene editing via direct self-assembly of Cas9 ribonucleoprotein complexes for cancer treatment, ACS Nano, 12, 7750, 10.1021/acsnano.8b01670 · DOI
- Qazi, 2016, Programmed self-assembly of an active P22-Cas9 nanocarrier system, Mol. Pharm., 13, 1191, 10.1021/acs.molpharmaceut.5b00822 · DOI
- Rouet, 2019, Efficient intracellular delivery of CRISPR-Cas ribonucleoproteins through receptor mediated endocytosis, ACS Chem. Biol., 14, 554, 10.1021/acschembio.9b00116 · DOI
- Park, 2019, In vivo neuronal gene editing via CRISPR-Cas9 amphiphilic nanocomplexes alleviates deficits in mouse models of Alzheimer's disease, Nat. Neurosci., 22, 524, 10.1038/s41593-019-0352-0 · DOI · Paper page
- Shen, 2018, CRISPR-delivery particles targeting nuclear receptor-interacting protein 1 (Nrip1) in adipose cells to enhance energy expenditure, J. Biol. Chem., 293, 17291, 10.1074/jbc.RA118.004554 · DOI
- Lostale-Seijo, 2017, Peptide/Cas9 nanostructures for ribonucleoprotein cell membrane transport and gene edition, Chem. Sci., 8, 7923, 10.1039/C7SC03918B · DOI
- Qiao, 2019, Cytosolic delivery of CRISPR/Cas9 ribonucleoproteins for genome editing using chitosan-coated red fluorescent protein, Chem. Commun., 55, 4707, 10.1039/C9CC00010K · DOI
- Zhu, 2019, DNAzyme activated protein-scaffolded CRISPR-Cas9 nanoassembly for genome editing, Chem. Commun., 55, 6511, 10.1039/C9CC03172C · DOI
- Yang, 2019, Nanoscale ATP-responsive zeolitic imidazole framework-90 as a general platform for cytosolic protein delivery and genome Editing, J. Am. Chem. Soc., 141, 3782, 10.1021/jacs.8b11996 · DOI · Paper page
- Liu, 2019, A boronic acid-rich dendrimer with robust and unprecedented efficiency for cytosolic protein delivery and CRISPR-Cas9 gene editing, Sci. Adv., 5, 10.1126/sciadv.aaw8922 · DOI · Paper page
- Campbell, 2019, Gesicle-mediated delivery of CRISPR/Cas9 ribonucleoprotein complex for inactivating the HIV provirus, Mol. Ther., 27, 151, 10.1016/j.ymthe.2018.10.002 · DOI
- Wang, 2018, ARMMs as a versatile platform for intracellular delivery of macromolecules, Nat. Commun., 9, 960, 10.1038/s41467-018-03390-x · DOI · Paper page
- Chen, 2019, Friend or foe? evidence indicates endogenous exosomes can deliver functional gRNA and Cas9 protein, Small, 15, 10.1002/smll.201970205 · DOI
- Pan, 2019, Near-infrared upconversion-activated CRISPR-Cas9 system: a remote-controlled gene editing platform, Sci. Adv., 5, 10.1126/sciadv.aav7199 · DOI · Paper page
- Zhou, 2018, Enhanced cytosolic delivery and release of CRISPR/Cas9 by black phosphorus nanosheets for genome editing, Angew. Chem. Int. Ed., 57, 10268, 10.1002/anie.201806941 · DOI · Paper page
- Mircetic, 2017, Purified Cas9 fusion proteins for advanced genome manipulation, Small Methods, 1, 1600052, 10.1002/smtd.201600052 · DOI
- Wang, 2017, Genome editing for cancer therapy: delivery of Cas9 protein/sgRNA plasmid via a gold nanocluster/lipid core-shell nanocarrier, Adv. Sci., 4, 1700175, 10.1002/advs.201700175 · DOI · Paper page
- Ha, 2017, Poly-sgRNA/siRNA ribonucleoprotein nanoparticles for targeted gene disruption, J. Control. Release, 250, 27, 10.1016/j.jconrel.2017.02.007 · DOI
- Zhu, 2019, Spatial control of in vivo CRISPR-Cas9 genome editing via nanomagnets, Nat. Biomed. Eng., 3, 126, 10.1038/s41551-018-0318-7 · DOI
- Cox, 2015, Therapeutic genome editing: prospects and challenges, Nat. Med., 21, 121, 10.1038/nm.3793 · DOI · Paper page
- Liu, 1996, Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection, Cell, 86, 367, 10.1016/S0092-8674(00)80110-5 · DOI · Paper page
- Bachtarzi, 2017, Ex vivo and in vivo genome editing: a regulatory scientific framework from early development to clinical implementation, Regen. Med., 12, 8, 10.2217/rme-2017-0095 · DOI
- Ormond, 2019, The clinical application of gene editing: ethical and social issues, Pers. Med., 16, 337, 10.2217/pme-2018-0155 · DOI
- Cho, 2014, Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases, Genome Res., 24, 132, 10.1101/gr.162339.113 · DOI · Paper page
- Bessis, 2004, Immune responses to gene therapy vectors: influence on vector function and effector mechanisms, Gene Ther., 11, S10, 10.1038/sj.gt.3302364 · DOI · Paper page
- Qi, 2018, Recent research and development of PLGA/PLA microspheres/nanoparticles: a review in scientific and industrial aspects, Front. Chem. Sci. Eng., 13, 14, 10.1007/s11705-018-1729-4 · DOI
- Baliou, 2018, CRISPR therapeutic tools for complex genetic disorders and cancer, Int. J. Oncol., 53, 443
- Baylis, 2017, First-in-human Phase 1 CRISPR gene editing cancer trials: are we ready?, Curr. Gene Ther., 17, 309
- Tang, 2016, Immune cell screening of a nanoparticle library improves atherosclerosis therapy, Proc. Natl. Acad. Sci. U. S. A., 113, E6731, 10.1073/pnas.1609629113 · DOI
- Jouannet, 2017, CRISPR-Cas9, germinal cells and human embryo, Biol. Aujourd'hui, 211, 207, 10.1051/jbio/2017032 · DOI
- Dever, 2017, The changing landscape of gene editing in hematopoietic stem cells: a step towards Cas9 clinical translation, Curr. Opin. Hematol., 24, 481, 10.1097/MOH.0000000000000385 · DOI · Paper page
Cited by
Engineering precision nanoparticles for drug delivery
Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0090-8 · Cited by 7,933
Mendes, B. B., Conniot, J., Avital, A., Yao, D., Jiang, X., Zhou, X., Sharf-Pauker, N., Xiao, Y., Adir, O., Liang, H., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00104-y · Cited by 719
CRISPR/Cas9 therapeutics: progress and prospects
Li, T., Yang, Y., Qi, H., Cui, W., Zhang, L., Fu, X., He, X., Liu, M., Li, P.-F., & Yu, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01309-7 · Cited by 719
CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy
Rosenblum, D., Gutkin, A., Kedmi, R., Ramishetti, S., Veiga, N., Jacobi, A. M., Schubert, M. S., Friedmann-Morvinski, D., Cohen, Z. R., Behlke, M. A., et al. (2020) · Science Advances · doi:10.1126/sciadv.abc9450 · Cited by 614
Wei, T., Cheng, Q., Min, Y.-L., Olson, E. N., & Siegwart, D. J. (2020) · Nature Communications · doi:10.1038/s41467-020-17029-3 · Cited by 590
Metadata
- Authors
- Xu, C.-F., Chen, G.-J., Luo, Y.-L., Zhang, Y., Zhao, G., Lu, Z.-D., Czarna, A., Gu, Z., & Wang, J.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 168
- Pages
- 3-29
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2991378064
- Cited by
- 184
- References
- 63
- FWCI
- 1.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Funders
- UCLA
- National Key R&D Program of China (2017YFA0205600)
- National Natural Science Foundation of China (81801825, 81901875, 81971723, 51633008)
- Program for Guangdong Introducing Innovative and Entrepreneurial Teams (2017ZT07S054)
- Guangdong Provincial Pearl River Talents Program (2017GC010713)
- Outstanding Scholar Program of Guangzhou Regenerative Medicine and Health Guangdong Laboratory (2018GZR110102001)
- Fundamental Research Funds for the Central Universities
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.